Colchicine Prescription for Gout with Renal Impairment

Introduction to Colchicine Treatment

• The American College of Rheumatology recommends prescribing low-dose colchicine (1.2 mg followed by 0.6 mg one hour later for acute flares, or 0.5-1 mg daily for prophylaxis) with mandatory dose reductions based on creatinine clearance, and absolutely avoid colchicine in patients with severe renal impairment (CrCl <30 mL/min) who are taking strong CYP3A4 or P-glycoprotein inhibitors 1, 2

Acute Gout Flare Treatment Dosing

• For patients with normal renal function, administer 1.2 mg at first sign of flare, followed by 0.6 mg one hour later, as this low-dose regimen is as effective as the older high-dose regimen but with significantly fewer gastrointestinal adverse events 1, 2, 3
• Treatment must be initiated within 12 hours of symptom onset for maximum effectiveness, though it can be given up to 36 hours after onset 1, 3

Prophylaxis Dosing

• Prescribe 0.5-1 mg daily for at least 6 months when initiating urate-lowering therapy, and continue for the greater of: 6 months OR 3 months after achieving target serum urate with no tophi detected 1, 4, 3

Critical Drug Interactions and Absolute Contraindications

• Do NOT prescribe colchicine to patients with renal OR hepatic impairment who are taking strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) or strong P-glycoprotein inhibitors (e.g., cyclosporine, ranolazine) 1, 2
• Fatal colchicine toxicity has been reported with cyclosporine and clarithromycin co-administration 5

Alternative Treatment Options When Colchicine is Contraindicated

• First-line alternatives include oral corticosteroids (e.g., prednisone 30-35 mg daily for 3-5 days) and NSAIDs (e.g., naproxen 500 mg twice daily, indomethacin 50 mg three times daily) until attack resolves 1, 2, 4, 3
• Intra-articular corticosteroids are also an option for monoarticular gout 1, 4

Important Safety Warnings

• Patients with renal impairment taking colchicine prophylaxis are at risk for neuromuscular toxicity and myopathy, especially when co-prescribed with statins 1, 5
• Monitor for muscle weakness, elevated creatine kinase, or neuropathy symptoms 1
• The most common adverse effects are diarrhea, nausea, vomiting, and abdominal cramping, and low-dose regimen has similar adverse event rates to placebo for acute treatment 2